Regenxbio: Q4 Earnings Insights
Portfolio Pulse from Benzinga Insights
Regenxbio (NASDAQ:RGNX) reported Q4 earnings with a miss on estimated earnings by -13.0%, posting an EPS of $-1.43 against an estimate of $-1.27. Revenue decreased by $9.13 million from the same period last year. In the previous quarter, the company beat EPS estimates which led to a 2.0% increase in share price the following day.
February 27, 2024 | 9:15 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Regenxbio reported a miss on Q4 earnings with an EPS of $-1.43, below the estimate of $-1.27, and a year-over-year revenue decrease of $9.13 million.
Missing earnings estimates typically leads to negative investor sentiment in the short term. The reported decrease in revenue further compounds the potential negative impact on RGNX's stock price. Historical data shows a positive stock price movement following an earnings beat last quarter, suggesting sensitivity to earnings reports.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100